Atea Pharmaceuticals Director Bruce Polsky Receives Equity Awards and Exercises RSUs

This Form 4 filing discloses equity transactions by Atea Pharmaceuticals director Bruce Polsky on June 18, 2026. The filing shows Polsky received 29,600 shares of common stock through the exercise of vested restricted stock units (RSUs) that had fully vested on that date. Additionally, he was granted 26,700 new RSUs that will vest in a single installment on the earlier of the next annual stockholders meeting after June 18, 2026 or June 18, 2027, contingent on continued service. He also received 37,700 stock options with an exercise price of $4.36 per share, which vest in twelve monthly installments beginning June 18, 2026, with full vesting by June 18, 2027. Following these transactions, Polsky holds 124,806 shares of common stock directly, 26,700 unvested RSUs, and 37,700 stock options. The filing was signed on June 23, 2026 by attorney-in-fact Andrea Corcoran.